Related Experiment Video

Updated: Aug 8, 2026

Isolation of Rat Portal Fibroblasts by In situ Liver Perfusion
07:39

Isolation of Rat Portal Fibroblasts by In situ Liver Perfusion

Published on: June 29, 2012

PPAR gamma inhibits growth of rat hepatic stellate cells and TGF beta-induced connective tissue growth factor

Kai Sun1, Qian Wang, Xiao-Hui Huang

  • 1Department of Hepatobiliary Surgery, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China.

Acta Pharmacologica Sinica
|May 26, 2006
PubMed
Abstract

Insights

Peroxisome proliferator-activated receptor gamma (PPAR gamma) activation inhibits hepatic stellate cell growth and connective tissue growth factor (CTGF) expression, showing potential for treating liver fibrosis.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Pharmacology

Background:

  • Hepatic stellate cells (HSC) play a crucial role in liver fibrosis.
  • Transforming growth factor beta (TGF-beta) signaling promotes HSC activation and extracellular matrix deposition.
  • Connective tissue growth factor (CTGF) is a key mediator in fibrotic processes.

Purpose of the Study:

  • To investigate the effect of peroxisome proliferator-activated receptor gamma (PPAR gamma) activation on rat HSC proliferation.
  • To determine the impact of PPAR gamma activation on TGF-beta-induced CTGF expression in HSC.
  • To evaluate PPAR gamma ligands as potential therapeutic agents for hepatic fibrosis.

Main Methods:

  • HSC were treated with PPAR gamma ligands (15-d-PGJ(2), GW7845) or an antagonist (GW9662).
  • Cell proliferation and apoptosis were assessed using MTT assay and flow cytometry.
  • CTGF mRNA and protein levels were quantified by RT-PCR and Western blotting, respectively.
  • Morphological changes were observed via electron microscopy.

Main Results:

  • PPAR gamma ligands significantly inhibited HSC proliferation and induced apoptosis in a dose-dependent manner.
  • PPAR gamma activation suppressed TGF-beta1-induced CTGF expression at both transcriptional and post-transcriptional levels.
  • Inhibitory effects were reversed by the PPAR gamma antagonist GW9662, confirming PPAR gamma mediation.
  • PPAR gamma activation shifted HSC phenotype from activated to quiescent.

Conclusions:

  • PPAR gamma ligands exhibit potent inhibitory effects on HSC growth and CTGF expression.
  • These findings highlight PPAR gamma as a promising therapeutic target for hepatic fibrosis.
  • PPAR gamma activation may serve as an antifibrotic strategy for prevention and treatment.

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Liver Regeneration01:24

Liver Regeneration

The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...